Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACTO: Tocilizumab + Gemcitabine/nab-Paclitaxel in Advanced Pancreatic Cancer
NCT02767557Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Jan 2017
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of tocilizumab in pancreatic cancer (PC), sponsored by Herlev Hospital. Started Jan 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02767557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767557.